for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Enochian Biosciences Inc

ENOB.OQ

Latest Trade

8.28USD

Change

-0.20(-2.36%)

Volume

79,257

Today's Range

8.13

 - 

8.49

52 Week Range

2.60

 - 

12.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.48
Open
8.49
Volume
79,257
3M AVG Volume
5.46
Today's High
8.49
Today's Low
8.13
52 Week High
12.99
52 Week Low
2.60
Shares Out (MIL)
52.22
Market Cap (MIL)
442.82
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Enochian Biosciences Announces FDA Acceptance Of Pre-IND Request For Potential Cure For Hepatitis B Virus Infection

Enochian Biosciences Announces Acquisition Of Exclusive License For Potential Pan-Coronavirus And Pan-Influenza Inhaled Treatment And Prevention Technology

Enochian Biosciences Announces FDA Acceptance Of Pre-Ind Request For Potential Hiv Cure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Enochian Biosciences Inc

Enochian BioSciences Inc. is a pre-clinical stage biotechnology company. The Company uses its cell, gene and immune therapy technologies for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, as well as to provide cancer remission in some of the deadliest cancers. The Company’s product candidates include ENOB-HV-01, an autologous transplant with genetically modified cells; ENOB-HV-11 and ENOB-HV-12, preventive and therapeutic vaccines; ENOB-HV-21, immunotherapy with allogeneic NK/GDT cells; ENOB-HV-31, in Vivo gene therapy; ENOB-HB-01, potential cure for HBV; ENOB-CV-01, Aerosol/Inhaled treatment potentially for all Coronaviruses that cause human disease; ENOB-CV-11, Aerosol/Inhaled prophylaxis potentially for all coronaviruses that cause human disease; ENOB-FL-01 Aerosol/Inhaled treatment potentially for all influenza viruses; and ENOB-FL-11, Aerosol/Inhaled prophylaxis potentially for all influenza viruses.

Industry

Biotechnology & Drugs

Contact Info

Century City Medical Plaza

2080 Century City East

LOS ANGELES, CA

90067

United States

+1.212.7630184

https://enochianbio.com/

Executive Leadership

Rene Sindlev

Independent Chairman of the Board

Mark Dybul

Chief Executive Officer

Luisa Puche

Chief Financial Officer

Henrik Gronfeldt-Sorensen

Director

Gregg Huber Alton

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.31
LT Debt To Equity (MRQ)
3.31
Return on Investment (TTM)
-14.66
Return on Equity (TTM)
-14.54

Latest News

Latest News

BRIEF-Enochian Biosciences Announces Successful Completion Of FDA Interact Meeting For Potential Cure For HIV

* ENOCHIAN BIOSCIENCES ANNOUNCES ITS SUCCESSFUL COMPLETION OF FDA INTERACT MEETING FOR A POTENTIAL CURE FOR HIV Source text for Eikon: Further company coverage:

BRIEF-Enochian Biosciences Announces Three Scientific Presentations On Potential HIV and HBV Cures

* ENOCHIAN BIOSCIENCES ANNOUNCES THREE SCIENTIFIC PRESENTATIONS ON POTENTIAL HIV AND HBV CURES Source text for Eikon: Further company coverage:

BRIEF-Enochian Biosciences Says Entered Into Agreement For $5 Mln In Unsecured, Non-Convertible Debt Note Purchase Agreement With Paseco Aps

* ENOCHIAN BIOSCIENCES -ON MARCH 27, ENTERED INTO AGREEMENT FOR $5 MILLION IN UNSECURED, NON-CONVERTIBLE DEBT NOTE PURCHASE AGREEMENT WITH PASECO APS Source: (https://bit.ly/2WZiGFq) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up